Walleye Capital
DNA icon

Walleye Capital’s Ginkgo Bioworks DNA Stock Holding History

Walleye Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,100
Closed -$34.1K – 4522
2025
Q4 		$34.1K Sell
4,100
-4,300
-51% -$46.3K ﹤0.01% 4160
2025
Q3 		$122K Buy
+8,400
New +$101K ﹤0.01% 3612
2025
Q1 		– Sell
-14,100
Closed -$138K – 4419
2024
Q4 		$138K Buy
14,100
+2,800
+25% +$24K ﹤0.01% 3966
2024
Q3 		$92.1K Buy
+11,300
New +$113K ﹤0.01% 4424

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's DNA Position: Q1 2026 in Review

Walleye Capital sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 5,079 shares — an estimated $42.2K sold.

Walleye Capital first reported a position in DNA in Q3 2024 and held it in 3 quarters. The position peaked at $2.61M in Q4 2024. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Walleye Capital reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 5,079 Ginkgo Bioworks shares in Q1 2026, an estimated $42.2K.
  • Walleye Capital first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 3 quarters.
  • Walleye Capital's Ginkgo Bioworks position peaked at $2.61M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.